Rifabutin dosage and administration: Difference between revisions
(Created page with "__NOTOC__ {{Rifabutin }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MYCOBUTIN (RIFABUTIN) CAPSULE [PHARMACIA A...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Dosage And Administration== | |||
It is recommended that MYCOBUTIN Capsules be administered at a dose of 300 mg once daily. For those patients with propensity to nausea, vomiting, or other gastrointestinal upset, administration of MYCOBUTIN at doses of 150 mg twice daily taken with food may be useful. For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the dose of MYCOBUTIN should be reduced by 50%. No dosage adjustment is required for patients with mild to moderate renal impairment. Reduction of the dose of MYCOBUTIN may also be needed for patients receiving concomitant treatment with certain other drugs (see Precautions-Drug Interactions).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MYCOBUTIN (RIFABUTIN) CAPSULE [PHARMACIA AND UPJOHN COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e1a6613-bdd3-4261-93b3-d7f5cc09064b | publisher = | date = | accessdate }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MYCOBUTIN (RIFABUTIN) CAPSULE [PHARMACIA AND UPJOHN COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e1a6613-bdd3-4261-93b3-d7f5cc09064b | publisher = | date = | accessdate }}</ref> | |||
Revision as of 00:10, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Dosage And Administration
It is recommended that MYCOBUTIN Capsules be administered at a dose of 300 mg once daily. For those patients with propensity to nausea, vomiting, or other gastrointestinal upset, administration of MYCOBUTIN at doses of 150 mg twice daily taken with food may be useful. For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the dose of MYCOBUTIN should be reduced by 50%. No dosage adjustment is required for patients with mild to moderate renal impairment. Reduction of the dose of MYCOBUTIN may also be needed for patients receiving concomitant treatment with certain other drugs (see Precautions-Drug Interactions).[1]
References
- ↑ "MYCOBUTIN (RIFABUTIN) CAPSULE [PHARMACIA AND UPJOHN COMPANY]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.